和鉑醫藥-B(02142.HK):新一代抗CTLA-4抗體HBM4003的I期數據摘要將於2021年ESMO年會上發佈
格隆匯7月26日丨和鉑醫藥-B(02142.HK)發佈公吿,公司在澳洲對晚期實體瘤患者進行的HBM4003(抗CTLA-4抗體)I期研究的臨牀數據摘要將以電子海報形式於2021年歐洲腫瘤內科學會(ESMO)年會上發佈,該年會預期將於2021年9月16日至21日舉行。該研究為一項開放標籤、劑量遞增的單藥治療晚期實體瘤療法研究。初步臨牀數據顯示,HBM4003的抗腫瘤療效令人鼓舞,並具有良好安全特性。HBM4003新穎和差異化的作用機制使其具有提高治療效果並顯著降低藥物毒性的潛力。
從該研究取得的數據已進一步證實HBM4003的臨牀前研究結果,即具有獨特的PK/PD特徵、新穎的作用機制及低免疫原性。鑑於該研究令人鼓舞的臨牀療效及安全性,公司已繼續進行多項針對實體瘤的全球Ib/IIa期試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.